Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era.
Chronic myeloid leukemia (CML) management varies across Asia due to disparities in affluence and healthcare provision. We surveyed CML management practice at 33 hospitals in 14 countries/regions to identify treatment challenges and opportunities for harmonization. Patients were generally treated according to international guidelines; however, tyrosine kinase inhibitors (TKIs) and molecular monitoring are inaccessible to many patients not covered by national insurance or eligible for subsidized treatment. Late diagnosis and suboptimal monitoring, often due to cost and accessibility issues, are challenges. Priorities for Asia include: extending accessibility to TKIs; specialist laboratory monitoring; and enriching data to support regional CML management guidelines.
Kim
Dong-Wook
DW
Division of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea. dwkim@catholic.ac.kr
Banavali
Shripad D
SD
Bunworasate
Udomsak
U
Goh
Yeow-Tee
YT
Ganly
Peter
P
Huang
He
H
Irving
Ian
I
Jootar
Saengsuree
S
Goh
Hyun-Gyung
HG
Koh
Liang-Piu
LP
Li
Wei
W
Naoe
Tomoki
T
Ng
Soo-Chin
SC
Purushotaman
Visalachy
V
Reksodiputro
Harryanto
H
Shih
Lee-Yung
LY
Tang
Jih-Luh
JL
Tojo
Arinobu
A
Wang
Jianmin
J
Wong
Raymond
R
D001208:Asia; D003625:Data Collection; D057210:Delayed Diagnosis; D016503:Drug Delivery Systems; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000191:economics / Q000628:therapy*; D010139:Pacific Islands; D010346:Patient Care Management / Q000191:economics; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors
D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases